Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 7,863,810 shares, an increase of 29.8% from the January 12th total of 6,056,385 shares. Currently, 7.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,965,603 shares, the days-to-cover ratio is currently 0.9 days.

In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction dated Friday, November 24th. The stock was bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Biopharmx (BPMX) remained flat at $$0.18 during mid-day trading on Friday. 8,203,840 shares of the company’s stock traded hands, compared to its average volume of 11,666,780. Biopharmx has a twelve month low of $0.10 and a twelve month high of $0.90. The company has a market cap of $25.50, a price-to-earnings ratio of -0.67 and a beta of 1.40.

Biopharmx (NYSEAMERICAN:BPMX) last announced its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05).

Separately, Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research note on Friday, December 8th.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.